Answers are grounded in this paper and cite their sources.
Locally advanced cervical cancer (LACC) accounts for a major healthcare burden in low- and middle-income countries, where five-year overall survival remains below 75% despite concurrent chemoradiation therapy (CCRT) as the curative standard. Treatment response is highly variable, yet clinical management is largely uniform. This review synthesizes current evidence on the genomic correlates of CCRT in LACC, spanning alterations in PIK3CA, PTEN, TP53, KRAS, ARID1A, and APOBEC-driven mutational signatures. These pathways offer biologically coherent explanations for radioresistance, but the strength and maturity of supporting evidence vary considerably, and evidence for most markers remains prognostic rather than treatment-predictive. No single genomic marker yet supports routine clinical use, and genome-only models omit complementary contributions from the tumor microenvironment, hypoxia, cancer stem cell biology, and clinicopathological or imaging-derived parameters. We further discuss the translational gap between genomic discovery and clinical implementation, with particular attention to population representation and resource constraints in high-burden settings. Prospective, population-inclusive genomic trials are urgently needed to translate these findings into equitable precision radiotherapy for patients with LACC worldwide.
No takes yet. Share an insight, caveat, or question.
Jayalie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: